Angus Wilfong, M.D. and Jerry Shih, M.D.
Recorded Saturday, December 6, 2014
This symposium presents an overview of the 8 newest antiepileptic drugs (AEDs) that include clobazam, eslicarbazepine, ezogabine, lacosamide, perampanel, rufinamide, stiripentol, and vigabatrin. Discussion covers the developmental history of the drug, mechanisms of action, indications for use, efficacy, safety issues, tolerability and ease of use to include drug interactions, formulations and dosing. Treatment paradigms that demonstrate the differential role of the medications are presented. Learners will have an understanding of how to incorporate the newest AEDs into an integrative treatment algorithm for their clinical practice and will be able to counsel patients and their families regarding risks, benefits and alternatives.
- Recognize opportunities in their clinical practice to use one or more of the eight newest AEDs and appropriately counsel patients regarding risks, benefits and alternatives
- Participate in counseling patients and their families regarding use of one or more of the eight newest AEDs
- Assist clinicians in their prescribing of one or more of the eight newest AEDs through an understanding of pharmacology and drug-to-drug interactions
- Assist in identifying tolerability of adverse effects in the use of one or more of the eight newest AEDs, particularly in reference to cognitive and behavioral outcomes.
Intermediate: Epilepsy fellows, epileptologists, epilepsy neurosurgeons, and other providers with experience in epilepsy care (e.g., advanced practice nurses, nurses, physician assistants), neuropsychologists, psychiatrists, basic and translational researchers.
Chair: Angus A. Wilfong, M.D.
Angus Wilfong, M.D.
Martin Brodie, M.D.
Elinor Ben-Menachem, M.D., Ph.D.
John Pollard, M.D.
Joan Conry, M.D.
Integration of New AEDs Into Clinical Practice
Bill Rosenfeld, M.D.
Angus A. Wilfong, M.D.